.png)
Natural history studies are vital for understanding disease progression, particularly in rare diseases. They provide a baseline to evaluate the effectiveness of new treatments. Our latest whitepaper explores the benefits and challenges associated with these studies.
This webinar is the second in a series on the complex legal environment of precision medicine, featuring Mina Frost, General Counsel for Sano Genetics. In this episode, Mina focuses on issues like market access, reimbursement, and intellectual property. Mina provides a clear breakdown of these topics, helping us understand how laws affect the delivery of innovative medical treatments.
Last week, our team had the opportunity to attend the World Orphan Drug Congress in Boston. The event was a dynamic gathering, where leaders from biopharma, regulatory agencies, and patient advocacy groups came together to discuss the challenges and advancements in treating rare diseases.
Newborn genome sequencing represents a major shift in paediatric healthcare, offering the potential for early detection of genetic disorders and setting the stage for personalised treatment strategies from the very beginning of life.
In the informative webinar hosted by Dr. Patrick Short, Co-founder and CEO of Sano Genetics, guest Dr. Andrea Gropman explored the profound impact of genetics and genomics on modern medical practice. The discussion provided valuable insights into the journey of translating genetic discoveries from the laboratory to the bedside, particularly focusing on neurogenetics and metabolic disorders.
Last week, Sano had the privilege of travelling to Boston for the Chief Medical Officer Summit 360°, where our Co-founder and COO, Charlotte Guzzo, shared her expertise on a panel focused on practical approaches to patient engagement. This event provided a platform for rich discussions on the shifting paradigms of drug development and precision medicine. Here, we’ll share an overview of key discussions and insights from the conference, emphasising the innovative strategies highlighted during the panels.
Natural history studies are instrumental in advancing precision medicine by offering a nuanced understanding of the patient journey across various diseases, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Huntington's Disease. This blog post explores the crucial role these studies play in disease modelling and the development of precisely targeted treatments within the realm of precision medicine.
This webinar, co-hosted by Sano Genetics and PrecisionLife, highlighted the complex nature of long Covid, which affects up to 30% of Covid-19 survivors and presents with more than 50 symptoms. The discussion brought to light the limitations of traditional genomic research, which has struggled to identify significant genetic risk factors, and underscored the necessity for innovative methodologies in understanding and treating this condition.
Liver disease remains one of the leading causes of morbidity and mortality worldwide, presenting complex challenges in healthcare due to its multifaceted nature and often silent progression. Advancements in genetic research have begun to illuminate the pathways through which liver diseases develop, revealing that conditions like metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), are not only influenced by lifestyle but also by genetic predispositions.
At Sano, our mission to accelerate the world’s transition to personalised medicine hinges on precise, individualised insights from vast amounts of health data. Understanding the sensitive nature of this data, we've committed to the highest standards of privacy and data protection, as detailed in our latest whitepaper, "Sano’s privacy promise."